RT Conference Proceedings
T1 Oral direct anticoagulants in the treatment of nonvalvular atrial fibrillation. Results of the daily clinical practice.
A1 Perez Villardon, B
A1 Garcia Bellon, AM
A1 Jimenez Rubio, C
A1 Rubio Alcaide, A
A1 Perez Benito, L
A1 Ramirez Marrero, MA
A1 De Mora Martin, M
A1 De Teresa Galvan, E
K1 Anticoagulantes
K1 Fibrilación atrial
K1 Fibrinolíticos
K1 Humanos
K1 Vitamina K
AB Atrial fibrillation (AF) is the most common arrhythmia. It leads to significant morbidity and mortality. The new oral anticoagulants (NOAC) represent an improvement compared with standard treatment (vitamin K antagonists(AVK)) in the prevention of thromboembolic complications in patients with non-valvular AF.
PB Ferrata Storti Foundation
SN 0390-6078
YR 2016
FD 2016-06
LK http://hdl.handle.net/10668/2439
UL http://hdl.handle.net/10668/2439
LA en
NO Perez Villardon B; Garcia Bellon AM, Jimenez Rubio C; Rubio Alcaide A, Perez Benito L, Ramirez Marrero MA, et al. Oral direct anticoagulants in the treatment of nonvalvular atrial fibrillation. Results of the daily clinical practice. Haematologica. 2016; 101 (s1) P410,
DS RISalud
RD Apr 8, 2025